How do your IL-7 fusion proteins address the high systemic toxicity often seen with native cytokines?

We prioritize targeted delivery and potency modulation. By fusing IL-7 to tumor-targeting fragments (such as scFv) or collagen-binding domains, we concentrate activity at the disease site. Furthermore, we employ engineered IL-7 variants or Fc-fusions to reduce off-target effects and improve the therapeutic window.

What starting materials do I need to provide to initiate a project on an IL-7 fusion protein?

To initiate the project, we typically require your therapeutic hypothesis, the sequence of your desired fusion partner, and any preliminary in vitro potency data you possess. This ensures our design phase is precisely aligned with your research goals, whether it involves lymphopenia models or T-cell targeting.

Antibody mediated IL-7 Targeting Service

Creative Biolabs offers specialized, comprehensive engineering solutions for Antibody-mediated IL-7 Targeting. We provide custom-designed, highly stable IL-7 fusion proteins and immune complexes optimized for specific immunological activities. Clients receive a preclinical lead candidate exhibiting confirmed superior pharmacokinetics, enhanced target specificity, and mitigated toxicity, positioning the asset for advanced preclinical testing and subsequent development transition. We transform complex cytokine challenges into high-yield, high-impact therapeutic assets.

Introduction to Antibody-mediated IL-7 Targeting Service

The strategic engineering of Interleukin-7 (IL-7) is necessary to mitigate its short serum half-life and potent pleiotropy, factors that commonly induce nonspecific effects. This development paradigm originated with the fusion of IL-2 and IL-12 to antibodies, capitalizing on the antibody's favorable pharmacokinetics and targeting capabilities. Contemporary antibody-mediated IL-7 targeting involves the genetic fusion with antibody fragments (Fc, scFv) or bioactive proteins (e.g., IL-15, GMCSF) to augment serum persistence via mechanisms such as FcRn recycling (exemplified by hIL-7-hyFc) and to control biodistribution, thereby substantially advancing the preclinical potential of IL-7.

For an in-depth analysis of how our services can be tailored to your specific project needs, request a consultation.

What We Can Offer

Customized Fusion Design and Engineering

Comprehensive and expert design and engineering of novel IL-7 fusion proteins, encompassing next-generation half-life extension formats, constructs for tumor-targeting, and synergistic multi-cytokine fusions. All designs are precisely tailored to the client's specific target cell population and desired biodistribution.

Optimized Pharmacokinetic (PK) Profile

Significant half-life extension is ensured through our proprietary platforms that leverage FcRn recycling, yielding consistent and predictable systemic persistence, a factor crucial for reduced dosing frequency.

Precision Potency Tuning

The bioactivity of IL-7 is finely regulated through the utilization of mutated IL-7 variants and IL-7/Anti-IL-7 immune complexes to modulate receptor binding and ensure the targeted expansion and survival of specific, therapeutically relevant T-cell subsets (e.g., CD8⁺ memory T cells).

Integrated Developability and Stability

We implement a developability first approach with a rigorous focus on optimizing fusion linkers and scFv stability from the initial design phase, minimizing aggregation and resulting in a robust and industrially scalable manufacturing process.

How Creative Biolabs Can Help

Why Choose Us?

Core Advantages	Unique Features
Validated Fusion Platforms	Expertise in advanced half-life extension formats, including Fc-fusions (hIL-7-hyFc) for superior PK and non-complement activation, and scDb formats for enhanced tumor targeting.
Precision Potency Modulation	We engineer mutated IL-7 variants and utilize IL-7/Anti-IL-7 immune complexes to fine-tune bioactivity, ensuring the fusion specifically targets and expands desired T-cell subsets (e.g., CD8⁺ memory T cells).
Combination Therapy Expertise	Documented success in developing IL-7 fusion proteins that synergize with contemporary immunotherapies, enhancing the efficacy of CAR-T cell therapy and Bi-specific T cell engagers in both hematological and solid tumor models.

Core Advantages

Unique Features

Validated Fusion Platforms

Expertise in advanced half-life extension formats, including Fc-fusions (hIL-7-hyFc) for superior PK and non-complement activation, and scDb formats for enhanced tumor targeting.

Precision Potency Modulation

We engineer mutated IL-7 variants and utilize IL-7/Anti-IL-7 immune complexes to fine-tune bioactivity, ensuring the fusion specifically targets and expands desired T-cell subsets (e.g., CD8⁺ memory T cells).

Combination Therapy Expertise

Documented success in developing IL-7 fusion proteins that synergize with contemporary immunotherapies, enhancing the efficacy of CAR-T cell therapy and Bi-specific T cell engagers in both hematological and solid tumor models.

To fully understand the Creative Biolabs advantage, we invite you to get a quote today.

Customer Reviews

FAQs

Related Services

scFv Generation and Optimization

Comprehensive services including affinity maturation via library screening, humanization of mouse-derived scFv, and stability optimization for critical fragments used in CAR-T and immunocytokine development.

Learn More →

Next Immunocytokine Engineering Development

Comprehensive engineering service for various cytokine-antibody fusions (e.g., IL-2, IL-15, IL-12) utilizing novel linkers and targeting moieties.